Impact of docetaxel plus ramucirumab on metastatic site in previously treated patients with non-small cell lung cancer: a multicenter retrospective study

BACKGROUND: Docetaxel (DOC) plus ramucirumab (RAM) has been recommended as an optimal therapy for previously treated patients with non-small cell lung cancer (NSCLC). In a clinical setting, there are few reports about DOC plus RAM, therefore its effect on factors such as Eastern Cooperative Oncology...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsumoto, Kinnosuke, Tamiya, Akihiro, Matsuda, Yoshinobu, Taniguchi, Yoshihiko, Atagi, Shinji, Kawachi, Hayato, Tamiya, Motohiro, Tanizaki, Satoshi, Uchida, Junji, Ueno, Kiyonobu, Yanase, Takafumi, Suzuki, Hidekazu, Hirashima, Tomonori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107751/
https://www.ncbi.nlm.nih.gov/pubmed/34012781
http://dx.doi.org/10.21037/tlcr-20-1263

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107751/
https://www.ncbi.nlm.nih.gov/pubmed/34012781
http://dx.doi.org/10.21037/tlcr-20-1263

Ejemplares similares